Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out

 
• By Jessica Merrill

The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.

Shelves
Biogen is shelving some pipeline assets to prioritize investment. • Source: Shutterstock

More from New Products

More from Scrip